Skip to site menu Skip to page content
Logo Image
In Brief
Spotlight

FDA places clinical hold on REGENXBIO’s RGX-121 in MPS II trial

The update follows the detection of asymptomatic findings in the spine MRIs of five participants enrolled in the CAMPSIITE study.

Latest news

US Executive Order 14420 and potential implications for diphtheria vaccination

Executive Order (EO) 14420, published 10 August 2026, declared two changes that would affect the diphtheria vaccine.

Industry and federally backed cancer trials diverge in goals, analysis finds

While the purpose of industry and federally backed cancer research differs, researchers say they play a complementary role in improving patient outcomes.

Liminatus Pharma selects Synex to advance CAR-T trial

The engagement follows authorisation from the Ministry of Food and Drug Safety of the Republic of Korea (MFDS).

Analysts praise intismeran’s landmark Phase III win, look to further data

Eyes are now on intismeran’s upcoming Phase II RCC readout, which they say could signal the drug’s wider potential across the solid tumour space.

Milestone’s etripamil nasal spray enters Phase III trial for atrial fibrillation

The primary goal of the ReVeRA-301 study is to achieve a reduction in ventricular rate within 30 minutes.